Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 698-710

  Devineni, Damayanthi ^a   Vaccaro, Nicole ^a   Polidori, David ^b   Rusch, Sarah ^b   Wajs, Ewa ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

canagliflozin; diuretic; drug drug interaction; hydrochlorothiazide; pharmacodynamics; pharmacokinetics; sodium glucose co transporter 2 (SGLT2) inhibitor; type 2 diabetes mellitus

Indexed keywords

BICARBONATE; CANAGLIFLOZIN; CHLORIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; POTASSIUM; SODIUM; URIC ACID; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD SAMPLING; CHLORIDE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; FAINTNESS; FEMALE; GEOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SODIUM BLOOD LEVEL; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URIC ACID BLOOD LEVEL; URINALYSIS; URINE VOLUME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEALTHY VOLUNTEERS; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; URINE; YOUNG ADULT;

EID: 84901472559     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.02.022     Document Type: Article

References (37)

1. R.A. Defronzo, J.A. Davidson, and S. Del Prato The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia Diabetes Obes Metab 14 2012 5 14
2. M.A. Abdul-Ghani, L. Norton, and R.A. Defronzo Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 2011 515 531
3. J. Rosenstock, N. Aggarwal, and D. Polidori et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
4. K. Stenlöf, W.T. Cefalu, and K.A. Kim et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
5. J.F. Yale, G. Bakris, and B. Cariou et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
6. G. Schernthaner, J.L. Gross, and J. Rosenstock et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 36 2013 2508 2515
7. B. Bode, K. Stenlöf, and D. Sullivan et al. Efficacy and safety of canagliflozin in older subjects with type 2 diabetes: a randomized trial Hosp Pract 41 2013 72 84
8. W.T. Cefalu, L.A. Leiter, and K.H. Yoon et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
9. F. Lavalle-González, A. Januszewicz, and J. Davidson et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2013 2582 2592
10. J.P. Wilding, G. Charpentier, and P. Hollander et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 2013 1267 1282
11. INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2013
12. D. Polidori, S. Sha, and A. Ghosh et al. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus J Clin Endocrinol Metab 98 2013 E867 E871
13. K. Stenlöf, W.T. Cefalu, and K.A. Kim et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 30 2014 163 175
14. M.R. Weir, A. Januszewicz, and R. Gilbert et al. Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) Diabetes 62 2013 A278 (Abstract 1077-P)
15. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
16. M.K. Ali, K.M. Bullard, and J.B. Saaddine et al. Achievement of goals in U.S. diabetes care, 1999-2010 N Engl J Med 368 2013 1613 1624
17. S.S. Ali, P.K. Sharma, and V.K. Garg et al. The target-specific transporter and current status of diuretics as antihypertensive Fundam Clin Pharmacol 26 2012 175 179
18. C.A. Ecelbarger, and S. Tiwari Sodium transporters in the distal nephron and disease implications Curr Hypertens Rep 8 2006 158 165
19. R.H. Barbhaiya, W.A. Craig, H.P. Corrick-West, and P.G. Welling Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods J Pharm Sci 71 1982 245 248
20. S. Shah, I. Khatri, and E.D. Freis Mechanism of antihypertensive effect of thiazide diuretics Am Heart J 95 1978 611 618
21. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
22. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine Guidance for Industry, Bioanalytical Method Validation 2001
23. C.T. Viswanathan, S. Bansal, and B. Booth et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays Pharm Res 24 2007 1962 1973
24. A.S. Levey, J. Coresh, and T. Greene et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 53 2007 766 772
25. S. Sha, D. Devineni, and A. Ghosh et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 2011 669 672
26. R.M. Lago, P.P. Singh, and R.W. Nesto Diabetes and hypertension Nat Clin Pract Endocrinol Metab 3 2007 667
27. D. Devineni, C.R. Curtin, and D. Polidori et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus J Clin Pharmacol 53 2013 601 610
28. D. Devineni, L. Morrow, and M. Hompesch et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes Obes Metab 14 2012 539 545
29. S. Nair, and J.P. Wilding Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 95 2010 34 42
30. A. Guyton, and J. Hall Textbook of Medical Physiology 2006 Elsevier Saunders Philadelphia, PA
31. K. Rave, L. Nosek, and J. Posner et al. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes - results of a hyperglycaemic glucose clamp study Nephrol Dial Transplant 21 2006 2166 2171
32. Janssen Research & Development LLC, Endocrinologic and Metabolic Drugs Advisory Committee. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. JNJ-28431754 (Canagliflozin). NDA 204042. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf. Accessed November 19, 2013.
33. E.D. Freis, A. Wanko, I.M. Wilson, and A.E. Parrish Chlorothiazide in hypertensive and normotensive patients Ann N Y Acad Sci 71 1958 450 455
34. P. van Brummelen, M. Schalekamp, and J. de Graeff Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension Acta Med Scand 204 1978 151 157
35. A.J. Reyes, W.P. Leary, and K. van der Byl et al. Renal excretory pharmacodynamics of diuretics in man: comparison between furosemide, hydrochlorothiazide and torasemide A.J. Reyes, W.P. Leary, Progress in Pharmacology, Vol. 6, No. 3: Clinical Pharmacology and Therapeutic Uses of Diuretics 1988 Gustav Fischer Stuttgart, Germany 83 151
36. K. Stefikova, V. Spustova, and R. Dzurik Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women Physiol Res 48 1999 327 330
37. B.A. Lamberg, and B. Kuhlback Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine Scand J Clin Lab Invest 11 1959 351 357